EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Defining homologous recombination deficiency status in pancreatic ductal adenocarcinoma: Clinical implications for evaluating response to platinum chemotherapy

Yanxia Wang, Fancheng Kong, Xiaohua Situ, Tiantian Yang, Tianqi Sun, Zhongpeng Xie, Pingling Wang, Yu Chen, Neng Jiang, Yu Dong, Zhaofan Luo, Zunfu Ke

Drug Resistance Updates · 2025-11 · 83 · 101291

DOI: 10.1016/j.drup.2025.101291 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2025-11. Verfasst von Yanxia Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China; Molecular Diagnosis and Gene Test Centre, Th…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Homologous Recombination, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Planning Project of Guangdong Province, National Natural Science Foundation of China, Guangzhou Municipal Science and Technology Program key projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Pancreatic ductal adenocarcinoma (PDAC) remains a daunting malignancy with limited therapeutic options; effective biomarkers are needed to improve its treatment decision-making. The aim of this study is to evaluate the role of homologous recombination deficiency (HRD) in assessing the response to platinum chemotherapy in PDAC. METHODS: A retrospective analysis was conducted on 264 patients diagnosed with PDAC. Tumor tissue samples were subjected to next-generation sequencing (NGS) to assess DNA damage repair (DDR) gene mutation landscape and HRD score. The integrated HRD score was calculated as the unweighted sum of loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transition (LST) scores. The associations between HRD status and clinical outcomes in patients receiving platinum treatment were systematically analyzed. RESULTS: Patients with BRCA1/2 biallelic loss-of-function (BILOF) status and/or an HRD score ≥ 42 were predefined as HRD-positive. According to this HRD status definition, 4.9 % (n = 13) of the 264 patients were identified as HRD-positive, identifying a broader population than using BRCA1/2 BILOF alone (1.9 %, n = 5). Patients with BRCA1/2 mutations (BRCA1/2 m), presented a lower frequency of alteration in genes related to non-homologous end joining (NHEJ) and mismatch repair (MMR) genes than those with BRCA1/2 wild-type (BRCA1/2 wt), with mutations observed in 46.15 % (6/13) of BRCA1/2 m versus 72.91 % (183/251) of BRCA1/2 wt patients. The median HRD score (23) in patients with DNA damage repair (DDR) gene BILOF mutations was notably higher than that in those with non-BILOF mutations in DDR genes (9). HRD-positive patients demonstrated markedly longer progression-free survival (PFS) (median PFS 44.1 months) than HRD-negative patients (median PFS 12.2 months) when the patients received first-line platinum-based adjuvant treatment (P = 0.035). Specifically, patients with BRCA1/2 BILOF exhibited a substantial clinical benefit from platinum therapy, with none of these patients experiencing disease progression or death during follow-up. CONCLUSIONS: BRCA1/2 BILOF plays a crucial role in identifying PDAC patients for first-line platinum-based adjuvant treatment, and HRD positive status, defined by BRCA1/2 BILOF and/or an HRD score ≥ 42, broadens the pool of eligible patients, and helps avoid ineffective treatment due to intrinsic drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsHomologous RecombinationAntineoplastic AgentsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedBRCA2 ProteinLoss of HeterozygosityBRCA1 ProteinHigh-Throughput Nucleotide SequencingAdultAged, 80 and over

Stichwörter der Autor:innen

Biallelic loss-of functionDrug resistanceHomologous recombination deficiencyPancreatic ductal adenocarcinomaPlatinum chemotherapy

Substanzen

BRCA2 ProteinBRCA2 protein, humanBRCA1 ProteinBRCA1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pathology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China; Molecular Diagnosis and Gene Test Centre, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080,…
  • Precision Scientific (Beijing) Co., Ltd., Beijing 100080, China.
  • Department of Pathology, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China.
  • Department of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.
  • State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou 510080, China; Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, Guangzhou 510080, China.
  • Precision Scientific (Beijing) Co., Ltd., Beijing 100080, China. Electronic address: dong.yu@puruijizhun.com.

Förderung

  • Science and Technology Planning Project of Guangdong Province
  • National Natural Science Foundation of China
  • Guangzhou Municipal Science and Technology Program key projects

Zitieren

APA

Wang, Y., Kong, F., Situ, X., Yang, T., Sun, T., Xie, Z., Wang, P., Chen, Y., Jiang, N., Dong, Y., Luo, Z., & Ke, Z. (2025). Defining homologous recombination deficiency status in pancreatic ductal adenocarcinoma: Clinical implications for evaluating response to platinum chemotherapy. Drug Resistance Updates, 83, 101291. https://doi.org/10.1016/j.drup.2025.101291

Vancouver

Wang Y, Kong F, Situ X, Yang T, Sun T, Xie Z, et al. Defining homologous recombination deficiency status in pancreatic ductal adenocarcinoma: Clinical implications for evaluating response to platinum chemotherapy. Drug Resistance Updates. 2025;83:101291. doi:10.1016/j.drup.2025.101291

BibTeX
@article{Wang2025,
  author = {Wang, Yanxia and Kong, Fancheng and Situ, Xiaohua and Yang, Tiantian and Sun, Tianqi and Xie, Zhongpeng and Wang, Pingling and Chen, Yu and Jiang, Neng and Dong, Yu and Luo, Zhaofan and Ke, Zunfu},
  title = {Defining homologous recombination deficiency status in pancreatic ductal adenocarcinoma: Clinical implications for evaluating response to platinum chemotherapy},
  journal = {Drug Resistance Updates},
  year = {2025},
  volume = {83},
  pages = {101291},
  doi = {10.1016/j.drup.2025.101291}
}
Kostenlos starten →